Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017
05 janv. 2017 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 5, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in controlling...
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016
05 déc. 2016 18h03 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study
31 oct. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 31, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
11 oct. 2016 08h10 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 11, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
15 sept. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
12 sept. 2016 19h07 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
22 août 2016 11h02 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
19 août 2016 08h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 19, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of devices for use in controlling bleeding and fluid loss in order...
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
15 août 2016 06h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
06 juin 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 6, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...